GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

Currently, GSK’s Shingrix is the only recombinant vaccine against herpes zoster, also known as shingles, approved for use in China. However, Ab&B’s chances of launching the second recombinant ...

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

Combining the science of the immune system and human genetics with advanced technologies is the cornerstone of R&D at GSK, underpinning a pipeline of 57 medicines and vaccines centred on ...